GlaxoSmithKline plans to cut 350 jobs, or 2% of its research staff, as part of an ongoing restructuring plan aimed at increasing productivity, according to a company statement.     “We continue to reshape our R&D operations to take advantage of new scientific opportunities and improve GSK’s productivity,” according to a company statement. “Regrettably some job reductions are necessary and we will do everything we can to support those employees who are affected.&#82...